Skip to main content

Table 2 Potential determinants for non-sentinel node metastases

From: Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases

Determinants

Category

Negative

Non-SN

Positive

Non-SN

OR 95% CI

OR 95% CIa

Screening

No

197

112

1.00

1.00

Yes

190

88

0.81 (0.58–1.15)

0.81 (0.54–1.21)

Unknown

4

11

4.84 (1.50–15.55)

4.70 (1.36–16.19)

Age

≤50

103

48

1.00

1.00

51–74

239

131

1.18 (0.79–1.76)

1.50 (0.53–2.06)

≥75

49

32

1.40 (0.80–2.46)

1.08 (0.45–2.60)

Menopause Status

Pre

104

49

1.00

1.00

Post <5ys

42

15

0.76 (0.38–1.50)

0.79 (0.34–1.86)

Post ≥5ys

231

139

1.28 (0.86–1.90)

1.21 (0.60–2.44)

Unknown

14

8

1.21 (0.48–3.08)

1.45 (0.52–4.05)

Tumour size

T1

220

111

1.00

1.00

T2

120

73

1.21 (0.83–1.74)

1.11 (0.74–1.66)

T3 & T4

6

4

1.32 (0.36–4.78)

0.78 (0.19–3.14)

Unknown

45

23

1.01 (0.58–1.76)

0.76 (0.40–1.44)

Tumour type

Ductal

331

159

1.00

1.00

D & L

5

9

3.75 (1.24–11.36)

2.93 (0.92–9.37)

Lobular

41

38

1.93 (1. 19-3.12)

1.73 (1.01–2.97)

Others

14

5

0.74 (0. 26-2.10)

0.85 (0. 29-2.50)

Histological grade

I

82

36

1.00

1.00

II

176

96

1.24 (0.78–1.98)

0.88 (0.53–1.46)

III

132

78

1.35 (0.83–2.18)

0.94 (0.54–1.65)

Unknown

1

1

2.28 (0. 14-37.43)

1.23 (0.07–21.34)

Estrogen receptor

Positive

358

187

1.00

1.00

Negative

33

23

1.33 (0.76–2.34)

1.04 (0.47–2.34)

Unknown

0

1

Progesterone receptor

Positive

319

159

1.00

1.00

Negative

72

50

1.40 (0.93–2.09)

1.17 (0.66–2.07)

Unknown

0

2

Her-2 status

Negative

248

135

1.00

1.00

Positive

33

28

1.56 (0.90–2.69)

1.52 (0.82–2.82)

Unknown

110

48

0.80 (0.54–1.19)

0.88 (0.55–1.39)

Multifocality

No

247

108

1.00

1.00

Yes

63

66

2.40 (1.59–3.62)

2.20 (1.41–3.44)

Unknown

81

37

1.04 (0.67–1.64)

0.99 (0.61–1.60)

Vascular invasion

No

166

75

1.00

1.00

Yes

60

31

1.14 (0.68–1.91)

1.13 (0.64–1.98)

Unknown

165

105

1.41 (0.98–2.03)

1.31 (0.86–1.99)

  1. aAdjusted for screening, age, menopause status, tumour size, tumour type, histological grade, estrogen status, progesterone status, HER2 status, multifocality, lymphovascular invasion